Shopping Cart 0
Cart Subtotal
USD 0

Microbiome-Targeted Therapeutics in Immunology

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 7995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 15990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 23985

Details

Microbiome-Targeted Therapeutics in Immunology

Summary

Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohn's disease, ulcerative colitis, and irritable bowel syndrome.

Scope

This report combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology. Components of the report include-

Overview of the Gut and Skin Microbiome: microbial dysbiosis by indication

Epidemiology Overview: prevalent or diagnosed prevalent cases by indication for the 16MM

Pipeline Assessment: promising late-stage products and early-stage pipeline by indication

Key Players: leading industry companies by indication

Clinical Trials Mapping and Design: trial breakdown by phase/indication and trial design by inidcation

Fecal Microbiota Transplants: opportunities and challenges for gastrointestinal indications

Pricing, Reimbursement and Regulatory Stategy: US payer perspective on late-stage therapies

Market Outlook: market potential estimation of late-stage therapies and key launch dates

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global microbiome market in immunology.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key pricing and reimbursement strategies.

READ MORE

Table Of Content

Scope

1 Table of Contents

1. Introduction

1.1 Related Reports

1.2 Upcoming Related Reports

2. Executive Summary

2.1 Key Findings

2.2 KOL and Payer Insight on Microbiome Competitive Landscape

3. Overview of the Gut and Skin Microbiome

3.1 Microbiome of the Skin

3.2 Microbiome in Atopic Dermatitis

3.3 Microbiome in Acne

3.4 Microbiome in Psoriasis

3.5 Microbiome of the Gut

3.6 Microbiome in Inflammatory Bowel Disease

3.7 Microbiome in Irritable Bowel Syndrome

4. Epidemiology Analysis

4.1 Epidemiology Analysis-Acne Vulgaris

4.2 Epidemiology Analysis-Atopic Dermatitis

4.3 Epidemiology Analysis-Psoriasis

4.4 Epidemiology Analysis-Crohn's Disease

4.5 Epidemiology Analysis-Ulcerative Colitis

4.6 Epidemiology Analysis-Irritable Bowel Syndrome

5. Pipeline Assessment

5.1 Overview of the Development of Pipeline Therapies

5.2 Pipeline Assessment-The Gut Microbiome

5.3 Qu Biologics' QBECO-SSI

5.4 Synthetic Biologics' SYN-010

5.5 Pipeline Assessment-The Skin Microbiome

5.6 AOBiome's B-244

5.7 Matrisys Bioscience's MSB-01

6. Key Players

6.1 Key Players-Companies Targeting the Microbiome

6.2 Analysis of Company Portfolio Gap-Gut Microbiome

6.3 Analysis of Company Portfolio Gap-Skin Microbiome

7. Clinical Trial Mapping and Design

7.1 Clinical Trial Mapping and Design-Gut Microbiome

7.2 Clinical Trial Mapping and Design-Skin Microbiome

8. Fecal Microbiota Transplants

8.1 Is Fecal Microbiota Transplant a Viable Option?

8.2 Clinical Trial Mapping and Design

9. Pricing, Reimbursement, and Regulatory Strategy

9.1 US Strategies for Gastrointestinal Indications

9.2 Payer Perspective on QBECO-SSI

9.3 Payer Perspective on SYN-010

9.4 US Strategies for Dermatology Indications

9.5 Payer Perspective on B-244

9.6 Payer Perspective on MSB-01

10. Market Outlook

10.1 Market Outlook for AOBiome's B-244

10.2 Market Outlook for Synthetic Biologics' SYN-010

10.3 Market Outlook for Qu Biologics' QBECO-SSI

10.4 Key Launch Dates for Pipeline Therapies

11. Appendix

11.1 Sources

11.2 Methodology

11.3 Primary Research

11.4 About the Authors

11.5 About GlobalData

11.6 Contact Us

11.7 Disclaimer

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Qu Biologics

Synthetic Biologics

4D Pharma

Enterome Bioscience

Second Genome

Seres Therapeutics

Rebiotix

Intrexon

Vedanta Biosciences

AOBiome

Matrisys Bioscience

SFA Therapeutics

Microbiome-Targeted Therapeutics in Immunology

Summary

Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohn's disease, ulcerative colitis, and irritable bowel syndrome.

Scope

This report combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology. Components of the report include-

Overview of the Gut and Skin Microbiome: microbial dysbiosis by indication

Epidemiology Overview: prevalent or diagnosed prevalent cases by indication for the 16MM

Pipeline Assessment: promising late-stage products and early-stage pipeline by indication

Key Players: leading industry companies by indication

Clinical Trials Mapping and Design: trial breakdown by phase/indication and trial design by inidcation

Fecal Microbiota Transplants: opportunities and challenges for gastrointestinal indications

Pricing, Reimbursement and Regulatory Stategy: US payer perspective on late-stage therapies

Market Outlook: market potential estimation of late-stage therapies and key launch dates

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global microbiome market in immunology.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key pricing and reimbursement strategies.

READ MORE

Scope

1 Table of Contents

1. Introduction

1.1 Related Reports

1.2 Upcoming Related Reports

2. Executive Summary

2.1 Key Findings

2.2 KOL and Payer Insight on Microbiome Competitive Landscape

3. Overview of the Gut and Skin Microbiome

3.1 Microbiome of the Skin

3.2 Microbiome in Atopic Dermatitis

3.3 Microbiome in Acne

3.4 Microbiome in Psoriasis

3.5 Microbiome of the Gut

3.6 Microbiome in Inflammatory Bowel Disease

3.7 Microbiome in Irritable Bowel Syndrome

4. Epidemiology Analysis

4.1 Epidemiology Analysis-Acne Vulgaris

4.2 Epidemiology Analysis-Atopic Dermatitis

4.3 Epidemiology Analysis-Psoriasis

4.4 Epidemiology Analysis-Crohn's Disease

4.5 Epidemiology Analysis-Ulcerative Colitis

4.6 Epidemiology Analysis-Irritable Bowel Syndrome

5. Pipeline Assessment

5.1 Overview of the Development of Pipeline Therapies

5.2 Pipeline Assessment-The Gut Microbiome

5.3 Qu Biologics' QBECO-SSI

5.4 Synthetic Biologics' SYN-010

5.5 Pipeline Assessment-The Skin Microbiome

5.6 AOBiome's B-244

5.7 Matrisys Bioscience's MSB-01

6. Key Players

6.1 Key Players-Companies Targeting the Microbiome

6.2 Analysis of Company Portfolio Gap-Gut Microbiome

6.3 Analysis of Company Portfolio Gap-Skin Microbiome

7. Clinical Trial Mapping and Design

7.1 Clinical Trial Mapping and Design-Gut Microbiome

7.2 Clinical Trial Mapping and Design-Skin Microbiome

8. Fecal Microbiota Transplants

8.1 Is Fecal Microbiota Transplant a Viable Option?

8.2 Clinical Trial Mapping and Design

9. Pricing, Reimbursement, and Regulatory Strategy

9.1 US Strategies for Gastrointestinal Indications

9.2 Payer Perspective on QBECO-SSI

9.3 Payer Perspective on SYN-010

9.4 US Strategies for Dermatology Indications

9.5 Payer Perspective on B-244

9.6 Payer Perspective on MSB-01

10. Market Outlook

10.1 Market Outlook for AOBiome's B-244

10.2 Market Outlook for Synthetic Biologics' SYN-010

10.3 Market Outlook for Qu Biologics' QBECO-SSI

10.4 Key Launch Dates for Pipeline Therapies

11. Appendix

11.1 Sources

11.2 Methodology

11.3 Primary Research

11.4 About the Authors

11.5 About GlobalData

11.6 Contact Us

11.7 Disclaimer

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Qu Biologics

Synthetic Biologics

4D Pharma

Enterome Bioscience

Second Genome

Seres Therapeutics

Rebiotix

Intrexon

Vedanta Biosciences

AOBiome

Matrisys Bioscience

SFA Therapeutics